Park National Corp OH decreased its stake in shares of Eli Lilly and Co. (NYSE:LLY) by 11.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,786 shares of the company’s stock after selling 11,392 shares during the period. Park National Corp OH’s holdings in Eli Lilly and were worth $7,126,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in LLY. Bath Savings Trust Co raised its stake in shares of Eli Lilly and by 0.4% in the third quarter. Bath Savings Trust Co now owns 20,572 shares of the company’s stock valued at $1,651,000 after buying an additional 80 shares during the last quarter. Cullinan Associates Inc. raised its stake in shares of Eli Lilly and by 0.9% in the third quarter. Cullinan Associates Inc. now owns 32,367 shares of the company’s stock valued at $2,598,000 after buying an additional 300 shares during the last quarter. Macquarie Group Ltd. raised its stake in shares of Eli Lilly and by 0.4% in the second quarter. Macquarie Group Ltd. now owns 426,150 shares of the company’s stock valued at $33,560,000 after buying an additional 1,700 shares during the last quarter. Carnick & Kubik Group LLC bought a new stake in shares of Eli Lilly and during the second quarter valued at about $686,000. Finally, Williams Jones & Associates LLC raised its stake in shares of Eli Lilly and by 341.1% in the second quarter. Williams Jones & Associates LLC now owns 12,130 shares of the company’s stock valued at $955,000 after buying an additional 9,380 shares during the last quarter. Institutional investors and hedge funds own 74.98% of the company’s stock.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and Co. (NYSE:LLY) traded down 1.34% during mid-day trading on Friday, hitting $76.67. 4,571,592 shares of the stock were exchanged. Eli Lilly and Co. has a 52-week low of $67.88 and a 52-week high of $88.16. The stock has a 50 day moving average of $78.23 and a 200-day moving average of $77.96. The stock has a market cap of $81.09 billion, a price-to-earnings ratio of 33.35 and a beta of 0.28.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by $0.08. The company earned $5.19 billion during the quarter, compared to the consensus estimate of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.89 earnings per share. Equities analysts predict that Eli Lilly and Co. will post $3.55 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be given a $0.51 dividend. The ex-dividend date is Thursday, November 10th. This represents a $2.04 dividend on an annualized basis and a yield of 2.66%. Eli Lilly and’s dividend payout ratio is presently 88.70%.

Several brokerages have issued reports on LLY. Citigroup Inc. reiterated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, November 8th. Jefferies Group reiterated a “buy” rating and set a $100.00 target price (down from $105.00) on shares of Eli Lilly and in a research report on Friday, October 28th. Societe Generale reiterated a “hold” rating and set a $78.00 target price on shares of Eli Lilly and in a research report on Thursday, October 27th. Goldman Sachs Group Inc. reiterated a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a research report on Wednesday, October 26th. Finally, Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $88.00 price objective for the company in a report on Thursday, October 20th. Two research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $96.74.

In related news, insider Maria A. Crowe sold 2,248 shares of the firm’s stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total value of $182,919.76. Following the completion of the sale, the insider now directly owns 94,319 shares in the company, valued at $7,674,737.03. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.20% of the stock is owned by corporate insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.